Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb 2:5:7-18.
doi: 10.2147/cia.s5476.

Management of hyperuricemia in gout: focus on febuxostat

Mattheus K Reinders  1 , Tim L Th A Jansen
Affiliations
Review

Management of hyperuricemia in gout: focus on febuxostat

Mattheus K Reinders et al. Clin Interv Aging. .

Abstract

Gout is the most common inflammatory arthritis in an elderly population, and can be diagnosed with absolute certainty by polarization microscopy. However, diagnosis may be challenging because atypical presentations are more common in the elderly. Management of hyperuricemia in the elderly with gout requires special consideration because of co-medication, contra-indications, and risk of adverse reactions. Urate-lowering agents include allopurinol and uricosuric agents. These also must be used sensibly in the elderly, especially when renal function impairment is present. However, if used at the lowest dose that maintains the serum urate level below 5.0 to 6.0 mg/dL (0.30 to 0.36 mmol/L), the excess urate in the body will eventually be eliminated, acute flares will no longer occur, and tophi will resolve. Febuxostat, a new xanthine oxidase inhibitor, is welcomed, as few alternatives for allopurinol are available. Its pharmacokinetics and pharmacodynamics are not significantly altered in patients with moderate renal function or hepatic impairment. Its antihyperuricemic efficacy at 80 to 120 mg/day is better than "standard dosage" allopurinol (300 mg/day). Long-term safety data and efficacy data on tophus diminishment and reduction of gout flares have recently become available. Febuxostat may provide an important option in patients unable to use allopurinol, or refractory to allopurinol.

Keywords: aging; febuxostat; gout; hyperuricemia; pharmacotherapy; xanthine oxidase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of febuxostat.
See this image and copyright information in PMC

References

    1. Singh H, Torralba KD. Therapeutic challenges in the management of gout in the elderly. Geriatrics. 2008;63(7):13–18. 20. - PubMed
    1. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(Suppl 1):S2. - PMC - PubMed
    1. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis. 2007;66(10):1269–1270. - PMC - PubMed
    1. Zhang W, Doherty M, Pascual E, et al. for EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout – Part I Diagnosis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65(10):1301–1311. - PMC - PubMed
    1. Zhang W, Doherty M, Bardin T, et al. for EULAR Standing Committee for International Clinical Studies Including Therapeutic. EULAR evidence based recommendations for gout – Part II Management: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65(10):1312–1324. - PMC - PubMed

MeSH terms